HEADER HYDROLASE 19-JUN-09 2WL0 TITLE HIV-1 PROTEASE INHIBITORS CONTAINING A TERTIARY ALCOHOL IN THE TITLE 2 TRANSITION-STATE MIMIC WITH IMPROVED CELL-BASED ANTIVIRAL ACTIVITY COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEASE; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: RESIDUES 501-599; COMPND 5 SYNONYM: HIV-1 PROTEASE, RETROPEPSIN, PR; COMPND 6 EC: 3.4.23.16; COMPND 7 ENGINEERED: YES; COMPND 8 MUTATION: YES; COMPND 9 OTHER_DETAILS: COMPLEX WITH INHIBITOR COMPOUND AHA599 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (Z2/CDC-Z34 SOURCE 3 ISOLATE); SOURCE 4 ORGANISM_COMMON: HIV-1; SOURCE 5 ORGANISM_TAXID: 11683; SOURCE 6 STRAIN: HIV-1 (D10); SOURCE 7 ATCC: 11676; SOURCE 8 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 9 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 10 EXPRESSION_SYSTEM_STRAIN: BL21(AI); SOURCE 11 EXPRESSION_SYSTEM_PLASMID: PEXP5 KEYWDS TRANSITION-STATE MIMIC, INHIBITOR, HYDROLASE EXPDTA X-RAY DIFFRACTION AUTHOR A.K.MAHALINGAM,L.AXELSSON,J.K.EKEGREN,J.WANNBERG,J.KIHLSTROM, AUTHOR 2 H.WALLBERG,B.SAMUELSSON,M.LARHED,A.HALLBERG,T.UNGE REVDAT 4 13-DEC-23 2WL0 1 REMARK REVDAT 3 17-JAN-18 2WL0 1 REMARK REVDAT 2 06-JUL-11 2WL0 1 JRNL REMARK FORMUL SHEET REVDAT 1 15-DEC-09 2WL0 0 JRNL AUTH A.K.MAHALINGAM,L.AXELSSON,J.K.EKEGREN,J.WANNBERG,J.KIHLSTR, JRNL AUTH 2 T.UNGE,H.WALLBERG,B.SAMUELSSON,M.LARHED,A.HALLBERG JRNL TITL HIV-1 PROTEASE INHIBITORS WITH A TRANSITION-STATE MIMIC JRNL TITL 2 COMPRISING A TERTIARY ALCOHOL: IMPROVED ANTIVIRAL ACTIVITY JRNL TITL 3 IN CELLS. JRNL REF J.MED.CHEM. V. 53 607 2010 JRNL REFN ISSN 0022-2623 JRNL PMID 19961222 JRNL DOI 10.1021/JM901165G REMARK 2 REMARK 2 RESOLUTION. 1.90 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.1 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.90 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 25.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 10000.000 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 83.0 REMARK 3 NUMBER OF REFLECTIONS : 15805 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.215 REMARK 3 FREE R VALUE : 0.244 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.200 REMARK 3 FREE R VALUE TEST SET COUNT : 805 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.009 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.90 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.00 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 86.00 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2557 REMARK 3 BIN R VALUE (WORKING SET) : 0.1990 REMARK 3 BIN FREE R VALUE : 0.2390 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.10 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 136 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.020 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1512 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 51 REMARK 3 SOLVENT ATOMS : 149 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.31900 REMARK 3 B22 (A**2) : 0.79400 REMARK 3 B33 (A**2) : -0.47500 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.23 REMARK 3 ESD FROM SIGMAA (A) : 0.05 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.28 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.06 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.006 REMARK 3 BOND ANGLES (DEGREES) : 1.197 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 25.20 REMARK 3 IMPROPER ANGLES (DEGREES) : 1.200 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT REMARK 3 KSOL : 0.42 REMARK 3 BSOL : 46.31 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : 559.PAR REMARK 3 PARAMETER FILE 3 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : 559.TOP REMARK 3 TOPOLOGY FILE 3 : WATER.TOP REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2WL0 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 19-JUN-09. REMARK 100 THE DEPOSITION ID IS D_1290040168. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 13-FEB-08 REMARK 200 TEMPERATURE (KELVIN) : 180 REMARK 200 PH : 5.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : MAX II REMARK 200 BEAMLINE : I911-3 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : NULL REMARK 200 DETECTOR MANUFACTURER : NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : CCP4 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 15805 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.900 REMARK 200 RESOLUTION RANGE LOW (A) : 15.800 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 86.0 REMARK 200 DATA REDUNDANCY : 4.300 REMARK 200 R MERGE (I) : 0.06000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 20.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.90 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.00 REMARK 200 COMPLETENESS FOR SHELL (%) : 87.7 REMARK 200 DATA REDUNDANCY IN SHELL : 4.10 REMARK 200 R MERGE FOR SHELL (I) : 0.11000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 10.00 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: PDB ENTRY 1D4J REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 53.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.73 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 2 MG/ML PROTEASE, 0.7 M NACL, 100 MM REMARK 280 MES PH5.5 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X+1/2,Y+1/2,-Z REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 29.16500 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 42.97500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 29.16500 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 42.97500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4060 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9270 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -24.1 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 ENGINEERED RESIDUE IN CHAIN A, LEU 563 TO PRO REMARK 400 ENGINEERED RESIDUE IN CHAIN A, VAL 582 TO THR REMARK 400 ENGINEERED RESIDUE IN CHAIN A, ILE 584 TO VAL REMARK 400 ENGINEERED RESIDUE IN CHAIN B, LEU 563 TO PRO REMARK 400 ENGINEERED RESIDUE IN CHAIN B, VAL 582 TO THR REMARK 400 ENGINEERED RESIDUE IN CHAIN B, ILE 584 TO VAL REMARK 700 REMARK 700 SHEET REMARK 700 DETERMINATION METHOD: DSSP REMARK 700 THE SHEETS PRESENTED AS "AB" IN EACH CHAIN ON SHEET RECORDS REMARK 700 BELOW IS ACTUALLY AN 7-STRANDED BARREL THIS IS REPRESENTED BY REMARK 700 A 8-STRANDED SHEET IN WHICH THE FIRST AND LAST STRANDS REMARK 700 ARE IDENTICAL. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 5AH A 1100 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2VG7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURES OF HIV-1 REVERSE TRANSCRIPTASE COMPLEXES WITH REMARK 900 THIOCARBAMATE NON- NUCLEOSIDE INHIBITORS REMARK 900 RELATED ID: 1AJV RELATED DB: PDB REMARK 900 HIV-1 PROTEASE IN COMPLEX WITH THE CYCLIC SULFAMIDE INHIBITOR AHA006 REMARK 900 RELATED ID: 1HAR RELATED DB: PDB REMARK 900 HIV-1 REVERSE TRANSCRIPTASE (AMINO-TERMINAL HALF) (FINGERS AND PALM REMARK 900 SUBDOMAINS) (RT216) REMARK 900 RELATED ID: 1HPS RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH SB206343 REMARK 900 RELATED ID: 1T7K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV PROTEASE COMPLEXED WITHARYLSULFONAMIDE REMARK 900 AZACYCLIC UREA REMARK 900 RELATED ID: 1D4J RELATED DB: PDB REMARK 900 HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR MSL370 REMARK 900 RELATED ID: 1R0A RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE COVALENTLYTETHERED REMARK 900 TO DNA TEMPLATE -PRIMER SOLVED TO 2.8 ANGSTROMS REMARK 900 RELATED ID: 1HPZ RELATED DB: PDB REMARK 900 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REMARK 900 RELATED ID: 2VG6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURES OF HIV-1 REVERSE TRANSCRIPTASE COMPLEXES WITH REMARK 900 THIOCARBAMATE NON- NUCLEOSIDE INHIBITORS REMARK 900 RELATED ID: 1HQE RELATED DB: PDB REMARK 900 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REMARK 900 RELATED ID: 1QE1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF 3TC-RESISTANT M184I MUTANT OF HIV-1 REVERSE REMARK 900 TRANSCRIPTASE REMARK 900 RELATED ID: 1NPA RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV-1 PROTEASE-HUP REMARK 900 RELATED ID: 1AJX RELATED DB: PDB REMARK 900 HIV-1 PROTEASE IN COMPLEX WITH THE CYCLIC UREA INHIBITOR AHA001 REMARK 900 RELATED ID: 1EBK RELATED DB: PDB REMARK 900 STRUCTURAL AND KINETIC ANALYSIS OF DRUG RESISTANT MUTANTS OF HIV-1 REMARK 900 PROTEASE REMARK 900 RELATED ID: 1TVR RELATED DB: PDB REMARK 900 HIV-1 RT/9-CL TIBO REMARK 900 RELATED ID: 1S6P RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1REVERSE REMARK 900 TRANSCRIPTASE (RT) IN COMPLEX WITH JANSSEN-R100943 REMARK 900 RELATED ID: 1IKV RELATED DB: PDB REMARK 900 K103N MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITHEFIVARENZ REMARK 900 RELATED ID: 1BQM RELATED DB: PDB REMARK 900 HIV-1 RT/HBY 097 REMARK 900 RELATED ID: 1W5Y RELATED DB: PDB REMARK 900 HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2- REMARK 900 SYMMETRIC INHIBITOR REMARK 900 RELATED ID: 1HOS RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEX WITH SB204144 REMARK 900 RELATED ID: 1IKW RELATED DB: PDB REMARK 900 WILD TYPE HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITHEFAVIRENZ REMARK 900 RELATED ID: 1S6Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) INCOMPLEX REMARK 900 WITH JANSSEN- R147681 REMARK 900 RELATED ID: 3HVT RELATED DB: PDB REMARK 900 REVERSE TRANSCRIPTASE REMARK 900 RELATED ID: 1EC1 RELATED DB: PDB REMARK 900 HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA409 REMARK 900 RELATED ID: 1EC0 RELATED DB: PDB REMARK 900 HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA403 REMARK 900 RELATED ID: 1T05 RELATED DB: PDB REMARK 900 HIV-1 REVERSE TRANSCRIPTASE CROSSLINKED TO TEMPLATE-PRIMERWITH REMARK 900 TENOFOVIR-DIPHOSPHATE BOUND AS THE INCOMINGNUCLEOTIDE SUBSTRATE REMARK 900 RELATED ID: 1RVQ RELATED DB: PDB REMARK 900 REVERSE TRANSCRIPTASE NON-NUCLEOSIDE BINDING SITE COMPLEXED WITH REMARK 900 TIBO (THEORETICAL MODEL) REMARK 900 RELATED ID: 1D4I RELATED DB: PDB REMARK 900 HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA425 REMARK 900 RELATED ID: 1MEU RELATED DB: PDB REMARK 900 HIV-1 MUTANT (V82F, I84V) PROTEASE COMPLEXED WITH DMP323 REMARK 900 RELATED ID: 1S9G RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) INCOMPLEX REMARK 900 WITH JANSSEN- R120394. REMARK 900 RELATED ID: 2BE2 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) INCOMPLEX REMARK 900 WITH R221239 REMARK 900 RELATED ID: 1HNV RELATED DB: PDB REMARK 900 HIV-1 REVERSE TRANSCRIPTASE (HIV-1 RT) MUTANT WITH CYS 280 REPLACED REMARK 900 BY SER (C280S) REMARK 900 RELATED ID: 1RVR RELATED DB: PDB REMARK 900 REVERSE TRANSCRIPTASE NON-NUCLEOSIDE BINDING SITE COMPLEXED WITH REMARK 900 IMIDAZODIPYRIDODIAZEPINE (UK -129,485) (THEORETICAL MODEL) REMARK 900 RELATED ID: 1IKX RELATED DB: PDB REMARK 900 K103N MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITHTHE REMARK 900 INHIBITOR PNU142721 REMARK 900 RELATED ID: 1W5W RELATED DB: PDB REMARK 900 HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2- REMARK 900 SYMMETRIC INHIBITOR REMARK 900 RELATED ID: 1IKY RELATED DB: PDB REMARK 900 HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH THE INHIBITORMSC194 REMARK 900 RELATED ID: 1QMC RELATED DB: PDB REMARK 900 C-TERMINAL DNA-BINDING DOMAIN OF HIV-1 INTEGRASE, NMR, 42 STRUCTURES REMARK 900 RELATED ID: 1N6Q RELATED DB: PDB REMARK 900 HIV-1 REVERSE TRANSCRIPTASE CROSSLINKED TO PRE-TRANSLOCATION AZTMP- REMARK 900 TERMINATED DNA (COMPLEX N) REMARK 900 RELATED ID: 1D4H RELATED DB: PDB REMARK 900 HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA435 REMARK 900 RELATED ID: 1RVN RELATED DB: PDB REMARK 900 REVERSE TRANSCRIPTASE NON-NUCLEOSIDE BINDING SITE COMPLEXED WITH REMARK 900 PHENYL-ISOINDOLINONE ( THEORETICAL MODEL) REMARK 900 RELATED ID: 1HBV RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH SB203238 REMARK 900 RELATED ID: 1HTF RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH GR126045 REMARK 900 RELATED ID: 1RTD RELATED DB: PDB REMARK 900 STRUCTURE OF A CATALYTIC COMPLEX OF HIV-1 REVERSE TRANSCRIPTASE: REMARK 900 IMPLICATIONS FOR NUCLEOSIDE ANALOG DRUG RESISTANCE REMARK 900 RELATED ID: 1EC2 RELATED DB: PDB REMARK 900 HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA428 REMARK 900 RELATED ID: 2HMI RELATED DB: PDB REMARK 900 HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH A DOUBLE-STRANDED REMARK 900 DEOXYRIBONUCLEIC ACID AND FAB28 REMARK 900 RELATED ID: 1W5V RELATED DB: PDB REMARK 900 HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2- REMARK 900 SYMMETRIC INHIBITOR REMARK 900 RELATED ID: 1SV5 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF K103N MUTANT HIV-1 REVERSETRANSCRIPTASE (RT) REMARK 900 IN COMPLEX WITH JANSSEN-R165335 REMARK 900 RELATED ID: 2UY0 RELATED DB: PDB REMARK 900 TWO-CARBON-ELONGATED HIV-1 PROTEASE INHIBITORS WITH A TERTIARY- REMARK 900 ALCOHOL-CONTAINING TRANSITION-STATE MIMIC REMARK 900 RELATED ID: 1HMV RELATED DB: PDB REMARK 900 HIV-1 REVERSE TRANSCRIPTASE REMARK 900 RELATED ID: 2BBB RELATED DB: PDB REMARK 900 STRUCTURE OF HIV1 PROTEASE AND HH1_173_3A COMPLEX. REMARK 900 RELATED ID: 1S9E RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) INCOMPLEX REMARK 900 WITH JANSSEN- R129385 REMARK 900 RELATED ID: 1N5Y RELATED DB: PDB REMARK 900 HIV-1 REVERSE TRANSCRIPTASE CROSSLINKED TO POST-TRANSLOCATION AZTMP- REMARK 900 TERMINATED DNA ( COMPLEX P) REMARK 900 RELATED ID: 1DLO RELATED DB: PDB REMARK 900 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REMARK 900 RELATED ID: 2WKZ RELATED DB: PDB REMARK 900 HIV-1 PROTEASE INHIBITORS CONTAINING A TERTIARY ALCOHOL IN THE REMARK 900 TRANSITION-STATE MIMIC WITH IMPROVED CELL-BASED ANTIVIRAL ACTIVITY REMARK 900 RELATED ID: 1HEG RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH SKF 107457 (HEG) REMARK 900 RELATED ID: 1RVP RELATED DB: PDB REMARK 900 REVERSE TRANSCRIPTASE NON-NUCLEOSIDE BINDING SITE COMPLEXED WITH REMARK 900 THIAZOLOISOINDOLINONE (THEORETICAL MODEL) REMARK 900 RELATED ID: 1RVL RELATED DB: PDB REMARK 900 REVERSE TRANSCRIPTASE NON-NUCLEOSIDE BINDING SITE COMPLEXED WITH REMARK 900 ALPHA-APA (R89439) (THEORETICAL MODEL) REMARK 900 RELATED ID: 1DW6 RELATED DB: PDB REMARK 900 STRUCTURAL AND KINETIC ANALYSIS OF DRUG RESISTANT MUTANTS OF HIV-1 REMARK 900 PROTEASE REMARK 900 RELATED ID: 1EET RELATED DB: PDB REMARK 900 HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH THE INHIBITOR MSC204 REMARK 900 RELATED ID: 1W5X RELATED DB: PDB REMARK 900 HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2- REMARK 900 SYMMETRIC INHIBITOR REMARK 900 RELATED ID: 1YT9 RELATED DB: PDB REMARK 900 HIV PROTEASE WITH OXIMINOARYLSULFONAMIDE BOUND REMARK 900 RELATED ID: 2B6A RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) INCOMPLEX REMARK 900 WITH THR-50 REMARK 900 RELATED ID: 1HTG RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH GR137615 REMARK 900 RELATED ID: 1HVU RELATED DB: PDB REMARK 900 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE COMPLEXED REMARK 900 WITH A 33-BASE NUCLEOTIDE RIBONUCLEIC ACID PSEUDOKNOT REMARK 900 RELATED ID: 1EBW RELATED DB: PDB REMARK 900 HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA322 REMARK 900 RELATED ID: 1RDH RELATED DB: PDB REMARK 900 HIV-1 REVERSE TRANSCRIPTASE (RIBONUCLEASE H DOMAIN) REMARK 900 RELATED ID: 2BAN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) INCOMPLEX REMARK 900 WITH JANSSEN- R157208 REMARK 900 RELATED ID: 1EBY RELATED DB: PDB REMARK 900 HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA369 REMARK 900 RELATED ID: 1J5O RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MET184ILE MUTANT OF HIV -1 REMARK 900 REVERSETRANSCRIPTASE IN COMPLEX WITH DOUBLE STRANDED DNA TEMPLATE- REMARK 900 PRIMER REMARK 900 RELATED ID: 1RVO RELATED DB: PDB REMARK 900 REVERSE TRANSCRIPTASE NON-NUCLEOSIDE BINDING SITE COMPLEXED WITH REMARK 900 NEVIRAPINE (THEORETICAL MODEL) REMARK 900 RELATED ID: 1HVP RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEX WITH SUBSTRATE ( THEORETICAL MODEL) REMARK 900 RELATED ID: 1MES RELATED DB: PDB REMARK 900 HIV-1 MUTANT (I84V) PROTEASE COMPLEXED WITH DMP323 REMARK 900 RELATED ID: 1EC3 RELATED DB: PDB REMARK 900 HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR MSA367 REMARK 900 RELATED ID: 1HEF RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH SKF 108738 (HEF) REMARK 900 RELATED ID: 1HIH RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH INHIBITOR CGP 53820 REMARK 900 RELATED ID: 1HNI RELATED DB: PDB REMARK 900 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE (HIV-1RT) REMARK 900 MUTANT WITH CYS 280 REPLACED BY SER (C280S) REMARK 900 RELATED ID: 1TV6 RELATED DB: PDB REMARK 900 HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH CP-94,707 REMARK 900 RELATED ID: 1A9M RELATED DB: PDB REMARK 900 G48H MUTANT OF HIV-1 PROTEASE IN COMPLEX WITH A PEPTIDIC INHIBITOR REMARK 900 U-89360E REMARK 900 RELATED ID: 1EBZ RELATED DB: PDB REMARK 900 HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA388 REMARK 900 RELATED ID: 2B5J RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) INCOMPLEX REMARK 900 WITH JANSSEN- R165481 REMARK 900 RELATED ID: 1HYS RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEXWITH A REMARK 900 POLYPURINE TRACT RNA:DNA REMARK 900 RELATED ID: 1MET RELATED DB: PDB REMARK 900 HIV-1 MUTANT (V82F) PROTEASE COMPLEXED WITH DMP323 REMARK 900 RELATED ID: 1T03 RELATED DB: PDB REMARK 900 HIV-1 REVERSE TRANSCRIPTASE CROSSLINKED TO TENOFOVIRTERMINATED REMARK 900 TEMPLATE-PRIMER (COMPLEX P) REMARK 900 RELATED ID: 1AXA RELATED DB: PDB REMARK 900 ACTIVE-SITE MOBILITY IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REMARK 900 PROTEASE AS DEMONSTRATED BY CRYSTAL STRUCTURE OF A28S MUTANT REMARK 900 RELATED ID: 1MER RELATED DB: PDB REMARK 900 HIV-1 MUTANT (I84V) PROTEASE COMPLEXED WITH DMP450 REMARK 900 RELATED ID: 1NPW RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV PROTEASE COMPLEXED WITH LGZ479 REMARK 900 RELATED ID: 3TLH RELATED DB: PDB REMARK 900 STRUCTURAL STUDIES OF HIV AND FIV PROTEASES COMPLEXED WITHAN REMARK 900 EFFICIENT INHIBITOR OF FIV PR REMARK 900 RELATED ID: 1SUQ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) INCOMPLEX REMARK 900 WITH JANSSEN- R185545 REMARK 900 RELATED ID: 2UXZ RELATED DB: PDB REMARK 900 TWO-CARBON-ELONGATED HIV-1 PROTEASE INHIBITORS WITH A TERTIARY- REMARK 900 ALCOHOL-CONTAINING TRANSITION-STATE MIMIC REMARK 900 RELATED ID: 1HVK RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR A76928 (S,S) REMARK 900 RELATED ID: 1SBG RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR SB203386 REMARK 900 RELATED ID: 1BQN RELATED DB: PDB REMARK 900 TYR 188 LEU HIV-1 RT/HBY 097 REMARK 900 RELATED ID: 1UWB RELATED DB: PDB REMARK 900 TYR 181 CYS HIV-1 RT/8-CL TIBO REMARK 900 RELATED ID: 2VG5 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURES OF HIV-1 REVERSE TRANSCRIPTASE COMPLEXES WITH REMARK 900 THIOCARBAMATE NON- NUCLEOSIDE INHIBITORS REMARK 900 RELATED ID: 1RVM RELATED DB: PDB REMARK 900 REVERSE TRANSCRIPTASE NON-NUCLEOSIDE BINDING SITE COMPLEXED WITH REMARK 900 HEPT (THEORETICAL MODEL) REMARK 900 RELATED ID: 1HTE RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH GR123976 REMARK 900 RELATED ID: 1HRH RELATED DB: PDB REMARK 900 RIBONUCLEASE H DOMAIN OF HIV-1 REVERSE TRANSCRIPTASE REMARK 900 RELATED ID: 1NPV RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH LDC271 REMARK 900 RELATED ID: 1HQU RELATED DB: PDB REMARK 900 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 DBREF 2WL0 A 1 99 UNP P03366 POL_HV1B1 501 599 DBREF 2WL0 B 101 199 UNP P03366 POL_HV1B1 501 599 SEQADV 2WL0 PRO A 63 UNP P03366 LEU 563 ENGINEERED MUTATION SEQADV 2WL0 THR A 82 UNP P03366 VAL 582 ENGINEERED MUTATION SEQADV 2WL0 VAL A 84 UNP P03366 ILE 584 ENGINEERED MUTATION SEQADV 2WL0 PRO B 163 UNP P03366 LEU 563 ENGINEERED MUTATION SEQADV 2WL0 THR B 182 UNP P03366 VAL 582 ENGINEERED MUTATION SEQADV 2WL0 VAL B 184 UNP P03366 ILE 584 ENGINEERED MUTATION SEQRES 1 A 99 PRO GLN ILE THR LEU TRP GLN ARG PRO LEU VAL THR ILE SEQRES 2 A 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET SER LEU PRO SEQRES 4 A 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO ILE GLU SEQRES 6 A 99 ILE CYS GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO THR ASN VAL ILE GLY ARG ASN LEU LEU THR SEQRES 8 A 99 GLN ILE GLY CYS THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP GLN ARG PRO LEU VAL THR ILE SEQRES 2 B 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET SER LEU PRO SEQRES 4 B 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO ILE GLU SEQRES 6 B 99 ILE CYS GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO THR ASN VAL ILE GLY ARG ASN LEU LEU THR SEQRES 8 B 99 GLN ILE GLY CYS THR LEU ASN PHE HET 5AH A1100 51 HETNAM 5AH METHYL [(1S)-1-({2-[(3S)-3-BENZYL-3-HYDROXY-4-{[(1S, HETNAM 2 5AH 2R)-2-HYDROXY-2,3-DIHYDRO-1H-INDEN-1-YL]AMINO}-4- HETNAM 3 5AH OXOBUTYL]-2-(4-PYRIDIN-2-YLBENZYL)HYDRAZINO}CARBONYL)- HETNAM 4 5AH 2,2-DIMETHYLPROPYL]CARBAMATE FORMUL 3 5AH C40 H47 N5 O6 FORMUL 4 HOH *149(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLY B 186 THR B 191 1 6 SHEET 1 AA 4 GLN A 2 ILE A 3 0 SHEET 2 AA 4 THR B 196 ASN B 198 -1 O LEU B 197 N ILE A 3 SHEET 3 AA 4 THR A 96 ASN A 98 -1 O THR A 96 N ASN B 198 SHEET 4 AA 4 GLN B 102 ILE B 103 -1 O ILE B 103 N LEU A 97 SHEET 1 AB 8 LEU A 10 ILE A 15 0 SHEET 2 AB 8 GLN A 18 LEU A 24 -1 O GLN A 18 N ILE A 15 SHEET 3 AB 8 VAL A 84 ILE A 85 1 N ILE A 85 O LEU A 23 SHEET 4 AB 8 VAL A 32 LEU A 33 -1 O VAL A 32 N VAL A 84 SHEET 5 AB 8 HIS A 69 VAL A 77 1 O LEU A 76 N LEU A 33 SHEET 6 AB 8 GLY A 52 ILE A 66 -1 O ARG A 57 N VAL A 77 SHEET 7 AB 8 LEU A 10 ILE A 15 -1 O LYS A 14 N GLU A 65 SHEET 8 AB 8 LEU A 10 ILE A 15 0 SHEET 1 BA 8 LEU B 110 ILE B 115 0 SHEET 2 BA 8 GLN B 118 LEU B 124 -1 O GLN B 118 N ILE B 115 SHEET 3 BA 8 VAL B 184 ILE B 185 1 N ILE B 185 O LEU B 123 SHEET 4 BA 8 VAL B 132 LEU B 133 -1 O VAL B 132 N VAL B 184 SHEET 5 BA 8 HIS B 169 VAL B 177 1 O LEU B 176 N LEU B 133 SHEET 6 BA 8 GLY B 152 ILE B 166 -1 O ARG B 157 N VAL B 177 SHEET 7 BA 8 LEU B 110 ILE B 115 -1 O LYS B 114 N GLU B 165 SHEET 8 BA 8 LEU B 110 ILE B 115 0 SITE 1 AC1 24 ARG A 8 ASP A 25 GLY A 27 ALA A 28 SITE 2 AC1 24 ASP A 29 ASP A 30 VAL A 32 GLY A 48 SITE 3 AC1 24 GLY A 49 ILE A 50 PRO A 81 HOH A2016 SITE 4 AC1 24 HOH A2068 HOH A2069 LEU B 123 ASP B 125 SITE 5 AC1 24 GLY B 127 ALA B 128 ASP B 129 GLY B 148 SITE 6 AC1 24 GLY B 149 ILE B 150 PRO B 181 HOH B2025 CRYST1 58.330 85.950 46.440 90.00 90.00 90.00 P 21 21 2 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017144 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011635 0.000000 0.00000 SCALE3 0.000000 0.000000 0.021533 0.00000